市場調查報告書
商品編碼
1468582
按類型(第一期和第二期梅毒、潛伏和三期梅毒)、檢測地點(實驗室檢測、照護端 (POC) 檢測)和地區分類的梅毒檢測市場 2024-2032Syphilis Testing Market by Type (Primary and Secondary Syphilis, Latent and Tertiary Syphilis), Location of Testing (Laboratory Testing, Point-of-Care (POC) Testing), and Region 2024-2032 |
IMARC Group年,全球梅毒檢測市場規模達12億美元。性傳染病(STD)的日益普及、流產發生率的增加以及醫療保健領域對有效疾病診斷和測試解決方案的需求不斷增加是推動市場發展的一些關鍵因素。
梅毒是指一種性傳染感染(STI),通常由性接觸引起,並透過皮膚或黏膜接觸在個體之間傳播。它開始時是生殖器和口腔直腸上的無痛潰瘍。如果不及時治療,可能會引發第三期梅毒的併發症,這種疾病可能會損害大腦、神經、血管和關節。目前,快速血漿反應素(RPR)和性病研究實驗室(VDRL)是從業人員正在使用的標準檢測方法。這些方法提供早期檢測,以便更好地治療,並減輕性傳染病 (STD) 的傳播和發展。因此,實驗室和照護端 (PoC) 中心經常使用梅毒檢測來診斷梅毒類型並確定其適當的治療方法。
對性病治療的認知不斷提高是推動市場成長的關鍵因素之一。據此,各國政府以及不同的非政府組織(NGO)正積極進行宣傳活動,提高民眾對預防性病(包括梅毒)和可用治療方案的認知。這反過來又促進了梅毒快速檢測試紙等梅毒檢測試劑盒的採用,從而有利地支持了市場成長。這些試劑盒提供家庭測試和有效的診斷結果,以便及時做出決策,這也有助於市場的成長。此外,這些測試套件使用方便,並且可以在網上零售店和店內藥房以實惠的價格輕鬆獲得,這也促進了市場的成長。除此之外,醫療保健領域的顯著改善以及最近推出有效治療替代方案的研發(R&D)活動正在對市場成長產生積極影響。此外,針對性傳播感染檢測的優惠醫療報銷政策的存在也促進了市場的成長。其他因素,例如包括梅毒在內的性病患病率不斷上升、無保護性交發生率上升、有效篩檢計畫的廣泛實施以及對疾病早期診斷的重視,正在為市場創造積極的前景。
The global syphilis testing market size reached US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 1.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032. The growing prevalence of sexually transmitted diseases (STDs), the increasing incidences of miscarriages, and the rising need for effective disease diagnosing and testing solutions in the healthcare sector represent some of the key factors driving the market.
Syphilis refers to a sexually transmitted infection (STI) that is usually caused by sexual contact and is spread amongst individuals through the skin or mucous membrane contact. It starts as a painless sore on the genitals and rectum of the mouth. If left untreated, it might trigger complications of tertiary syphilis, wherein the disease may damage the brain, nerves, blood vessels, and joints. At present, rapid plasma reagin (RPR) and venereal diseases research laboratory (VDRL) are standard testing practices that are being used by practitioners. These approaches provide early detection for better treatment and mitigate the spread and development of sexually transmitted diseases (STDs). As a result, syphilis testing is frequently used in laboratories and point-of-care (PoC) centers to diagnose the syphilis type and identify its proper treatment.
The increasing awareness regarding STD treatment represents one of the key factors driving the market growth. In line with this, governments of various nations, along with different non-governmental organizations (NGOs) are actively undertaking campaigns to sensitize the common mass regarding the prevention of STDs, including syphilis, and the available treatment options. This, in turn, is facilitating the adoption of syphilis testing kits, such as syphilis rapid test strips, which is favorably supporting the market growth. These kits offer at-home testing with effective diagnostic results, and thus timely decision-making, which is also contributing to the market growth. Additionally, the convenience of usage and the easy availability of these test kits at online retail stores and in-store pharmacies at affordable price points are contributing to the market growth. Apart from this, the considerable improvements in the healthcare sector and the recent research and development (R&D) activities to launch effective treatment alternatives are positively impacting the market growth. Moreover, the presence of favorable medical reimbursement policies for the testing of sexually transmitted infections is contributing to the market growth. Other factors, such as the increasing prevalence of STDs, including syphilis, rising incidences of unprotected sexual intercourse, the widespread implementation of effective screening programs, and an enhanced focus on the early diagnostic of the disease, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each segment of the global syphilis testing market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type and location of testing.
Primary and Secondary Syphilis
Latent and Tertiary Syphilis
The report has also provided a detailed breakup and analysis of the syphilis testing market based on the type. This includes primary and secondary, and latent and tertiary syphilis. According to the report, primary and secondary syphilis represented the largest segment.
Laboratory Testing
Point-of-Care (POC) Testing
A detailed breakup and analysis of the syphilis testing market based on the location of testing has also been provided in the report. This includes laboratory and point-of-are (POC) testing. According to the report, laboratory testing accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for syphilis testing. Some of the factors driving the North America syphilis testing market included the increasing prevalence of STDs, significant technological advancements, and extensive research and development (R&D) activities.
The report has also provided a comprehensive analysis of the competitive landscape in the global syphilis testing market. Detailed profiles of all major companies have also been provided. Some of the companies covered includes Abbott Laboratories, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, DRG International Inc. (BioCheck Inc.), F. Hoffmann-La Roche AG, Siemens Healthineers AG (Siemens AG), Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.